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Abstract
Background: Hypoacetylation on histone H3 of human prostate cancer cells has been described. Little is known about
the modifications of other histones from prostate cancer cells.
Methods: Histones were isolated from the prostate cancer cell line DU-145 and the non-malignant prostatic cell line
RC170N/h. Post-translational modifications of histone H2B were determined by liquid chromatography-mass
spectrometry (LC-MS)/MS.
Results: The histone H2B of the prostate cancer cell line DU-145 was found to have hypoacetylation, hypomethylation,
and dephosphorylation as compared to the non-malignant prostatic cell line RC170N/h. H2B regained acetylation on
multiple lysine residues, phosphorylation on Thr19, and methylation on Lys23 and Lys43 in the DU-145 cells after sodium
butyrate treatment.
Conclusions: The histone H2B of DU-145 prostate cancer cells are hypoacetylated, hypomethylated, and
dephosphorylated. Histone deacetylase inhibitor reversed this phenotype. Epigenetic agent may therefore be
useful for prostate cancer therapy and worth further investigation.
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To the editor
The histone proteins H3 and H4 hetero-tetramer are
flanked on each side by an H2A and H2B hetero-dimer,
with H3-H4 and H2A-H2B each interacting with differ-
ent parts of the nucleosomal DNA. Aberrant activities of
DNA methyltransferases and acetyltransferases lead to
epigenetic remodeling of chromatin and have been
implicated in carcinogenesis [1–3]. At this time, not
much is known about the post-translational modifica-
tions of histones other than H3 in prostate cancer cells.
Recent studies in yeast have revealed the importance of
H2B in transcriptional regulation [4]. In this study, post-
translational modifications of histone H2B from the
human prostate cancer cell line DU-145 and the non-
malignant prostatic cell line RC170N/h were analyzed by
liquid chromatography-mass spectrometry (LC-MS/MS)
(see Additional file 1) [5–7]. The status of H2B acetyl-
ation in DU-145 cells was illustrated in Fig. 1a, with
acetylation determined on a single lysine (K) residue at
amino acid sequence position 20 (K20). Lysine at
position 23 (K23) was found to be di-methylated as
shown in Fig. 1a. The acetylation at K20 and di-
methylation at K23 were observed on the tryptic pep-
tides, 16KAVTKAQK23 and 17AVTKAQKKDGKK28.
Analyses of H2B from RC170N/h cells revealed acetyl-
ation at K5, K16, and K20 (Fig. 1b). The methylations
were found to be tri-methylated at K15 and K120, di-
methylated at K23, and mono-methylated at K116
(Fig. 1b). The same peptides 16KAVTKAQK23 and
17AVTKAQKKDGKK28 that were analyzed for the
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DU-145 cells, together with other peptides including
1PDPSKSAPAPKKGSKKAVTKAQK23 and 109HAVSEG
TKAVTK120, were examined for these modifications.
The non-malignant RC170N/h cells clearly had more
acetylated and methylated lysine residues on H2B
than the DU-145 cancer cells.
To evaluate the histone deacetylase (HDAC) activity,
DU-145 cells were treated with sodium butyrate, an in-
hibitor of HDACs. After butyrate treatment of these
cells, acetylation on lysine residues, K5, K11, K12, K16,
K20, and K27 of H2B, was identified (Fig. 1c). Specific-
ally, the acetylation changes were detected in the
following peptides, 6SAPAPKKGSK15, 16KAVTKAQK23,
1PEPAKSAPAPK11, and 17AVTKAQKKDGKK28. The
fact that acetylation on H2B in the DU-145 cells was
detected in multiple additional lysine residues after
HDAC inhibition by sodium butyrate suggests that there
was an excessive HDAC activity in the DU-145 cells.
Acetylation of K5, K16, and K20 was also observed in
the non-malignant RC170N/h cells (Fig. 1b, c). These
data showed that the DU-145 cancer cells had a single
K20 acetylation site, compared to the non-malignant
RC170N/h cells that had three sites at K5, K16, and K20.
The NaB-treated DU-145 cells had six acetylation sites
at K5, K11, K12, K16, K20, and K27. The differences in
the acetylation sites were detected at the N termini,
without involving the alpha helices which start at amino
acid residue 37 of H2B (Fig. 1, underscored sequences).
The small lung carcinoma cells have six sites at K5, K11,
K12, K15, K16, and K20 [8]; The Jurkat cells have three
sites at K12, K15, and K20 [9], whereas the untreated
DU-145 cells in this study have one acetylated K20.
These results indicate that there are clear differences in
acetylation sites among the human cell lines. These
differences constitute the epigenetic signatures of
individual neoplastic clones.
We next examined changes of the H2B methylation
status in the DU-145 cells upon HDAC inhibition. After
sodium butyrate treatment, additional methylation on
K43 was found (Fig. 2c), as compared to only K23
methylation in the untreated DU-145 cells (Fig. 1a).
There was no obvious phosphorylation detected on
histone H2B peptides from the DU-145 prostate cancer
cells. However, phosphorylation was detected at serines
Fig. 1 Post-translational modifications on the histone H2B. a The acetylation and methylation sites of H2B in the human prostate cancer DU-145 cells.
b The acetylation, methylation, and phosphorylation of H2B in the non-malignant prostatic RC170N/h cells. c Histone H2B modifications in the DU-145
cells after sodium butyrate treatment. indicates acetylation, indicates methylation, indicates di-methylation, indicates tri-methylation,
and indicates phosphorylation. The H2B histone sequence is presented at the lower part of the figure. The underscored sequences represent the
alpha helices in the structured domains of the histone
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S6 and S14, as well as threonines T19 and T115 of the
H2B histone in the non-malignant prostatic RC170N/h
cells (Fig. 1b). Phosphorylation was detected on H2B
peptides, 16KAVTKAQK23, 1PDPSKSAPAPKKGSKKA
VTKAQK23, and 109HAVSEGTKAVTK120. When the
DU-145 cells were treated with sodium butyrate (NaB),
phosphorylation was found on threonine T19 (Fig. 1c).
The increase in phosphorylation of H2B in DU-145 cells
after NaB treatment is particularly intriguing. This
provides the first evidence of the possible cross talk of
HDACs and serine/threonine kinases.
As illustrated in Fig. 2, we postulate that the abnormal
HDAC activity could turn the reversible histone modifi-
cations into irreversible, leading to perpetual aberrant
epigenomes. An enhanced HDAC activity or a reduced
K-acetyltransferase activity would tip the balance towards
deacetylation. These could perpetuate the epigenetic
changes and result in carcinogenesis. Targeting epigenetic
modifications by inhibiting HDACs and DNA methyltrans-
ferases has become novel cancer therapies [2, 3, 10–12].
This study also suggests that HDAC inhibitors may be a
potential therapeutic option for prostate cancer.
In conclusion, the histone H2B of DU-145 prostate
cancer cells are hypoacetylated, hypomethylated, and
dephosphorylated. Histone deacetylase inhibitor re-
versed this phenotype. Epigenetic agent may therefore
be useful for prostate cancer therapy and worth
further investigation.
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Fig. 2 Hypothetical pathways of carcinogenesis from prostatic stem cells. Histone hypoacetylation leads to disruption of the normal epigenome in
prostatic stem cells. The aberrant epigenome with hypoacetylation may be established when the reversible alterations in acetylation become irreversible.
This is due to the abnormal histone deacetylase activities. As a result, caretaker phenotype and critical genes are inactivated. These eventually lead
to carcinogenesis
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